Human pituitary tumor transforming gene (PTTG) overexpression correlates with metastasis in multiple tumors, and yet its molecular mechanisms of action remain elusive. We detected PTTG overexpression in 66% (111 of 169) of primary esophageal squamous cell carcinoma (ESCC) tumor tissues by in situ hybridization. PTTG overexpression correlated with lymph node metastasis (P < 0.05). Ectopic PTTG overexpression in a representative ESCC cell line, EC9706, increased in vitro cell migration and invasion and promoted in vivo lymph node metastasis. Suppressing PTTG expression by siRNA decreased cell motility in both PTTG-HA/EC9706 and KYSE150 cells. By using mass spectrometric analysis, we identified that PTTG up-regulated S100A4 and galectin-1 secretion and down-regulated tissue inhibitor of metalloproteinase-2 secretion to the culture media. PTTG induced S100A4 and galectin-1 mRNA and protein expression as assessed by Western blot and reverse transcription-PCR. Attenuating galectin-1 expression by siRNA constrained PTTG-HA/EC9706 cell motility (P < 0.05). PTTG activated E-box transcription and induced c-Myc protein expression in EC9706 cells, which in turn may act on an E-box motif within the galectin-1 promoter. Chromatin immunoprecipitation assays further confirmed specific c-Myc binding to galectin-1 promoter. PTTG-induced galectin-1 transactivation and expression were mediated by c-Myc, and both inductions were suppressed by c-Myc RNAi cotranfection. These findings elucidate the molecular mechanisms of PTTG overexpression in promoting tumor metastasis, whereby upregulated PTTG modulates expression and secretion of metastasis-related factors to facilitate cell motility. [Cancer Res 2009;69(8):3283-90] 
Introduction
Human esophageal cancer is the eighth most common cancer and the sixth leading cause of death from cancer worldwide (1) . In China, esophageal squamous cell carcinoma (ESCC) is the most prevalent type (2) . ESCC occurs at a high frequency in southern and eastern Africa, Japan, and especially in certain areas of China (1, 2) . Despite recent advances achieving in multimodality therapies, the overall 5-year survival rate of ESCC is very low, although it has recently increased from 4% in the 1970s to 16% in the United States and to 10% in Europe (1, 2) . Spread of neoplastic cells into lymph nodes and distant organs leads to poor therapy and survival of ESCC patients. Accumulating evidence indicates that as a poor prognostic factor (3, 4) , lymph node metastasis correlates with ESCC patient survival. Therefore, the identification of target genes for the determination of tumor progression is urgently required for ESCC diagnostic and therapeutic development.
Pituitary tumor transforming gene (PTTG) was first isolated from rat pituitary tumor cells in 1997 and has been identified as an oncogene because PTTG overexpression induces cellular transformation in vitro and tumor formation in nude mice (5) . As human securin, PTTG participates in mitotic spindle checkpoint pathway and inhibits sister chromatid separation to ensure chromosomal stability (6, 7) . In contrast to restricted normal tissue expression, PTTG is abundantly expressed in pituitary (8) , thyroid (9) , and breast cancers (10) and other non-endocrine-related cancers such as colon (11) , gastric (12) , lung (8, 13) , and esophageal cancers (14, 15) . PTTG overexpression correlates with metastasis and poor overall survival in various human cancers (10-13, 15, 16) . Notably, PTTG has been identified as one of the key ''signature genes'' to predict metastasis in primary adenocarcinomas of the lung, breast, and prostate and medulloblastomas (17) . Although PTTG has been reported to stimulate vascular endothelial growth factor (VEGF), basic fibroblast growth factor, and matrix metalloproteinase (MMP)-2 secretion (5, 9, (18) (19) (20) , the precise mechanism by which PTTG contributes to metastasis is still poorly understood.
In the present study, we investigated how PTTG facilitates human ESCC metastasis. We found that PTTG overexpression correlated with lymph node metastasis in 169 primary ESCC tumor tissues. In vitro and in vivo cellular function experiments showed that PTTG promoted the invasive and migratory capacity of esophageal cancer cells. We detected that PTTG regulated the secretion and/or expression of S100A4, galectin-1, and tissue inhibitor of metalloproteinase (TIMP)-2. Furthermore, suppressing galectin-1 expression by siRNA decreased PTTG-promoted cell motility in PTTG-HA/EC9706 cells. Reporter assays indicated that PTTG transactivated c-Myc in EC9706 cells, and of interest, an E-box motif was observed in galectin-1 promoter. Chromatin immunoprecipitation assays confirmed that c-Myc specifically binds to the galectin-1 promoter and that this binding is enhanced by PTTG overexpression in EC9706 cells. Transfection of c-Myc siRNA attenuated PTTG-induced galectin-1 transactivation and overexpression. These results suggest that PTTG increases galectin-1 expression mediated, at least partially, by c-Myc, thereby enhancing ESCC motility.
Materials and Methods
Tissue specimens. ESCC tumor specimens and paired normal tissues were collected by the Pathology Department of Cancer Hospital. The protocol was approved by Institutional Review Board.
In situ hybridization and immunohistochemistry. In situ hybridization and immunohistochemistry were done as described previously (14) . Specimens were incubated with anti-PTTG (securin, Abcam; 1:50) antibody at 4jC overnight for immunohistochemistry; mouse IgG was used as negative control.
Cell culture and transfections. EC9706 and KYSE150 cells were cultured as described previously (14) . Transfections were done in 80% to 90% confluency by Lipofectamine 2000 (Invitrogen). Stable transfectants were selected with 400 Ag/mL G418 for 14 d. Predesigned galectin-1 siRNAs and negative control siRNA were obtained from Ambion.
In vitro cell invasion and migration assays. Cell invasion and migration assays were done in chemotaxis chambers (Neuro Probe). Cells (6 Â 10 4 ) were suspended in 50 AL serum-free medium and added to the upper chamber. The lower chamber was filled with complete medium. Polycarbonate membrane (8 Am) coated with culture medium containing 20 AL/mL Matrigel was placed between the two chambers. Cells were invaded at 37jC for 36 hours. After removing noninvaded cells, the membrane was fixed in methanol and stained with Giemsa. Invaded cells were photographed and quantified in 10 random fields per membrane. Each sample was assayed in triplicate. As analyzed by Student's t test, P < 0.05 indicated statistical significance. A similar system, with uncoated polycarbonate membrane, was used for migration assay.
Experimental metastasis in vivo. PTTG-HA/EC9706 or pcDNA 3 /EC9706 cells (10 6 cells/100 AL) were injected into female nude mice via tail vein. Each group included 12 mice of ages 6 to 8 wk. Mice were sacrificed 4 wk later and examined for metastasis development. Lungs and visibly observable lymph nodes were separately stained with H&E and PTTG.
Evaluation and statistical analysis. Semiquantitative reverse transcription-PCR (RT-PCR) and Western blot results were quantified by GEL-PRO analyzer according to densitometry. Relative mRNA or protein expression levels (detected gene/h-actin) were calculated from quantified data. The ratio of detected mRNA/protein expression level to that of normalized control was used as fold changes of expression. Ratio >2.0 was regarded as up-regulation, 0.5 to 2.0 as no change, and <0.5 as down-regulation.
For in situ hybridization, PTTG expression was scored by staining intensity and stained cell percentage. Tissues with no staining were rated as 0; with weak staining or moderate to strong staining in V5% of cells as 1; with moderate or strong staining in 6% to 25% of cells as 2; with strong staining in 26% to 50% of cells as 3; and with strong staining in z50% of cells as 4. A delta score of tumor tissues minus matched normal epithelia was used to evaluate the extent of PTTG overexpression (V0 as negative; z1 as positive). A similar method was used to evaluate PTTG immunohistochemistry staining. Score 2 to 4 was regarded as positive expression, and score 0 to 1 was regarded as negative expression. Correlations were analyzed by SPSS10.0. P < 0.05 was considered significant. Two-dimensional electrophoresis. PTTG-HA/EC9706 and pcDNA 3 / EC9706 cells were cultured to 80% to 90% confluency and serum starved for 24 hours. Supernatant proteins in culture media were collected, condensed, and dehydrated (30 Ag/gel) overnight with 18-cm immobilized pH gradient strips. Electrofocusing was done at 56 kVh using IPGphor (Amersham) at 20jC. Focused strips were equilibrated and treated by reduction of DTT and alkylation of iodoacetamide, then transferred onto 12% uniform SDSpolyacrylamide gels using Ettan DALT II system (Amersham). Separated proteins stained with silver nitrate. Images were acquired and analyzed by combination of ImageMaster Platinum 5.0 and manual visualization.
Differential protein identification by matrix-assisted laser desorption/ionization-time of flight mass spectrometry. Significantly altered spots were separated by spot picker P2D1.5 (The Gel Company). Particles were treated by reduction of DTT and alkylation of iodoacetamide, incubated with 25 mmol/L NH 4 HCO 3 containing 0.05 Ag/AL trypsin at 37jC overnight, and centrifuged. Supernatants were mixed with 2 AL of 1% trifluoroacetic acid (TFA), loaded on anchor chip, and mixed with matrix solution consisting of a-cyano-4-hydroxycinnamic acid in 70% acetonitrile with 0.1% TFA. After drying and desalting with 0.1% TFA at room temperature, spots were analyzed by Bruker AutoFlex matrix-assisted laser desorption/ ionization-time of flight mass spectrometry (MALDI-TOF MS). Mass spectrometry was done under 19-kV accelerating voltage in reflection mode with m/z range of 700 to 3,500. Obtained monoisotopic peptide masses were analyzed by m/z software and interpreted with MASCOT (Matrix Science) against the Swiss-port database.
Chromatin immunoprecipitation. Chromatin immunoprecipitation was done using Chromatin Immunoprecipitation Kit & Shearing Kit (Active Motif). Cells ( 10 7 ) were cross-linked and lysed. Chromatin was sheared to 300-to 900-bp fragments. Normalized inputs were incubated with 4 Ag antic-Myc antibody (Santa Cruz) or negative control IgG at 4jC overnight. Immunoprecipitated DNA was amplified by PCR using the galectin-1 promoter primers, which span the À821 to À650 bp region flanking the putative E-box (at À744 bp) in human galectin-1 promoter ( forward, 5 ¶-GGGCGACAGAGCGAGACTC-3 ¶; reverse, 5 ¶-GGCAGGCAGGGGATAGT-CAAA-3 ¶).
Results
PTTG overexpression correlates with lymph node metastasis in 169 primary ESCC tissues. PTTG mRNA expression was measured in 169 primary ESCC samples and paired normal tissues by in situ hybridization. In normal epithelia, 92% (155 of 169) of specimens were not immunoreactive for PTTG (Fig. 1D ), whereas 8% (14 of 169) of normal tissues exhibited positive PTTG staining in the basal layer of normal epithelia, where vigorous cell proliferation occurs (Fig. 1C) . In contrast, 66% (111 of 169) of ESCC tumors exhibited strong PTTG staining (delta score z1; Fig. 1A ), and 34% (58 of 169) of ESCC tumors showed negative or weak PTTG staining (delta score V0; Fig. 1B ). In all 169 ESCC tumors, 80 specimens were detected with lymph node metastasis. PTTG overexpression was more often in metastatic than in nonmetastatic ESCC tumors. In the 80 tumors with lymph node metastasis, PTTG overexpression was observed in 74% (59 of 80) of samples, whereas in other 89 tumors without metastasis, only 58% (52 of 89) of tumors exhibited high PTTG expression. Statistical analysis indicated that PTTG overexpression significantly correlated with lymph node metastasis in ESCC (Pearson m 2 test, P < 0.05; Table 1 ). PTTG promotes migration and invasion of esophageal cancer cells. As we reported previously (14) , EC9706 expresses lower endogenous PTTG compared with other ESCC cell lines. Thus, we used EC9706 to generate PTTG stable cell lines. The PTTG-HA/EC9706 stable cells expressed high exogenous HAtagged PTTG, and the pcDNA 3 /EC9706 cells were used as empty vector control ( Supplementary Fig. S1A ). In vitro cell migration and invasion assays showed that enhanced PTTG expression promoted both the migration and invasion abilities of EC9706 cells. The migration ability of PTTG-HA/EC9706 cells increased f4.4-fold and invasion ability increased f3.1-fold compared with pcDNA 3 / EC9706 control cells ( Fig. 2A) . In contrast, transfection of PTTG RNAi in PTTG-HA/EC9706 cells strongly attenuated PTTG expression up to 80% ( Supplementary Fig. S1A ) and resulted in a significant decrease of both migration (57%; P < 0.05) and invasion (62%; P < 0.05; Fig. 2A ), whereas PTTG-HA/EC9706 cells transfected with negative RNAi control did not show any difference (P > 0.05; Supplementary Fig. S1A ; Fig. 2A) . Supplementary Fig. S1A shows exogenous HA-tagged PTTG expression in four different EC9706 cells by Western blot.
Furthermore, we examined the influence of endogenous PTTG on ESCC cell migration and invasion. Transfecting PTTG RNAi in KYSE150 cells that express abundant PTTG (14) attenuated endogenous PTTG expression ( Supplementary Fig. S1B ) and decreased both migration and invasion up to 50% compared with RNAi control transfection (P < 0.05; Fig. 2B ). In brief, both results in EC9706 and KYSE150 cells indicate that high PTTG expression promotes ESCC cell migration and invasion.
PTTG promotes lymph node metastasis in nude mice. To investigate whether PTTG promotes in vivo metastasis, we injected PTTG-HA/EC9706 and pcDNA 3 /EC9706 cells into nude mice through tail veins. Mice were sacrificed 4 weeks later; no metastatic carcinomas were observed in lungs (data not shown). In the PTTG-HA/EC9706-injected group, 90% (9 of 10) of mice developed lymph node metastases, accompanied with positive PTTG staining (Fig. 3A) ; in the control group with negative PTTG staining, 75% (9 of 12) of mice exhibited lymph node metastases, and the other 25% (3 of 12) of mice failed to detect any lymph node metastasis (Fig. 3B) . The incidence of lymph node metastasis in PTTG-HA/ EC9706 group (90%) was higher than in control (75%), but the difference was not significant (t test, P > 0.05) because the EC9706 control was already a highly malignant cell line. Nevertheless, the percentage of metastatic lymph nodes with respect to the total visibly observable lymph nodes per mouse was significantly higher in PTTG-HA/EC9706 group (87%) than in control group (53%; t test, P < 0.05; Fig. 3C ). The result indicates that PTTG promotes in vivo lymph node metastasis.
Proteomic profiles of serum-free conditioned media collected from PTTG-HA/EC9706 and pcDNA 3 /EC9706 control cells. We used two-dimensional electrophoresis combined with MALDI-TOF MS methods to compare secretion protein profiles between conditioned media collected from PTTG-HA/EC9706 and pcDNA 3 /EC9706 cells. As shown in Fig. 4A , the electrophoretic patterns of PTTG-HA/EC9706 and control were similar. All spots were evenly distributed along a wide isoelectric point range, and most spots distributed along a molecular mass range around and above 14 kDa. We duplicated protein extraction and twodimensional electrophoresis to ensure result reliability; thus, four two-dimensional electrophoresis images were analyzed for each group. Statistical imaging analysis presented 340 F 1 silver-stained spots on PTTG-HA/EC9706 two-dimensional electrophoresis gel and 325 F 3 spots on pcDNA 3 /EC9706. More than 90% of twodimensional electrophoresis spots were overlapped in these parallel gels for both samples. These data confirmed the reproducibility and reliability of parallel two-dimensional electrophoresis images for differential analysis.
Analysis, identification, and validation of different PTTGrelated two-dimensional electrophoresis spots: PTTG regulates S100A4, galectin-1, and TIMP-2 secretion. We compared All different spots were excised and processed for mass spectrometric analysis. Thirty-five of 58 spots were identified as proteins, including 8 down-regulated and 27 up-regulated proteins. In the 35 spots, 27 unique proteins were assigned, including 6 proteins found in multiple spots, such as peroxiredoxin-1 ( found in four spots), a-enolase, D-dopachrome decarboxylase, fumarate hydratase, peroxiredoxin-2, and protein DJ-1 ( found in two spots), suggesting that these proteins exhibit distinct modified forms and their modification and secretion were altered by PTTG overexpression. MALDI-TOF MS results were summarized in Supplementary Tables S1 to S3. Supplementary Fig. S2 depicts a comprehensive TIMP-2 spectrum of MALDI-TOF MS. Notably, among the 27 identified proteins, six proteins have been reported as important metastasis-related molecules. Secretion of S100A4 (spot b in Fig. 4B ), galectin-1 (spot c in Fig. 4B ), S100A6, and thioredoxin was increased, whereas secretion of TIMP-1 and TIMP-2 (spot a in Fig. 4B ) was decreased, in the culture media of PTTG-HA/EC9706 cells.
To further confirm the mass spectrometric results, we assessed protein secretion level in cell culture media by Western blot. As shown in Fig. 4C , secretion of S100A4 and galectin-1 was upregulated, whereas TIMP-2 secretion was down-regulated, in PTTG-HA/EC9706 cells compared with pcDNA 3 /EC9706 controls. These data are consistent with the proteomic results. In contrast, impairing PTTG expression by RNAi decreased the secretion of S100A4 and galectin-1 and increased TIMP-2 secretion (Fig. 4C) . Similar results were obtained in KYSE150 cells (Supplementary Fig. S3 ).
PTTG regulates expression of S100A4, galectin-1, and TIMP-2 in ESCC cell lines. In addition to protein secretion, we detected expression of S100A4, galectin-1, and TIMP-2 in PTTG-HA/ EC9706 and pcDNA 3 /EC9706 cells by RT-PCR and Western blot. As exhibited in Supplementary Fig. S4 , both mRNA and protein levels of S100A4 and galectin-1 were up-regulated in PTTG-HA/EC9706 cells compared with pcDNA 3 /EC9706 controls. In contrast, suppressing PTTG overexpression by RNAi decreased both mRNA and protein expression of S100A4 and galectin-1 in PTTG-HA/ EC9706 cells. These results agree with the above proteomic data. Interestingly, although TIMP-2 mRNA level was elevated in PTTG-HA/EC9706 cells and was attenuated by PTTG siRNA, TIMP-2 protein levels were not altered. Similar results were obtained in KYSE150 cells. Transient transfection of PTTG RNAi in KYSE150 cells impaired endogenous PTTG expression and attenuated S100A4 and galectin-1 expression (Supplementary Fig. S5 ).
Suppressing galectin-1 expression decreases migration and invasion of PTTG-HA/EC9706 cells. Galectin-1 facilitates metastasis by promoting cell migration, invasion, angiogenesis, and evasion of immune response in various tumors (21) (22) (23) (24) (25) . To assess whether galectin-1 is required for PTTG-induced migration and invasion, we suppressed galectin-1 expression in PTTG-HA/EC9706 cells by siRNA. Two different galectin-1 RNAis (RNAi-1 and RNAi-2) were transiently transfected into PTTG-HA/EC9706 cells, which led to a decreased detection of galectin-1 protein levels by Western blot 48 hours later. Galectin-1 RNAi-1 suppressed protein expression better than did RNAi-2 (Fig. 5A) . Thus, we transfected galectin-1 RNAi-1 into PTTG-HA/EC9706 cells for further in vitro cell invasion and migration assays. Suppressing galectin-1 in PTTG-HA/EC9706 cells resulted in reduction of both cell migration and invasion up to 50% ( Fig. 5B ; P < 0.05). These results imply that PTTG overexpression promoted cell migration and invasion, mediated, at least partially, by galectin-1.
PTTG activates galectin-1 transcription by inducing c-Myc expression and E-box transactivation. PTTG functions as a transcription factor alone (26) and also collaborates with cofactors to regulate target genes. In accordance with a previous report in HeLa cells (26), we found that PTTG induced c-Myc expression in EC9706 cells. Transient PTTG-HA-pcDNA 3 transfection increased c-Myc expression f2.6-fold in EC9706 cells ( Supplementary  Fig. S6A ). The induction was suppressed f60% by cotransfecting PTTG RNAi (pSilencer-PTTG) and completely abolished by cotransfecting c-Myc RNAi (pSilencer-c-Myc). c-Myc acts as a transcription factor by binding target gene promoters that contain a consensus DNA sequence, GTGCAC (c-Myc binding element, also called E-box), and regulating their transcriptional activity (26, 27) . In addition to c-Myc expression increase, PTTG also induced E-box transcriptional activity f2.8-fold in EC9706 cells as assessed by dual luciferase reporter assay. The transactivation was attenuated f30% by cotransfecting PTTG RNAi and totally abolished by cotransfecting c-Myc RNAi (Supplementary Fig. S6B ). The results suggest that PTTG induces c-Myc expression and consequently regulates c-Myc target gene transcription.
An E-box motif was scanned in human galectin-1 promoter, which located at À744 bp upstream of transcription start site. We cloned the 1.3-kb galectin-1 promoter containing the putative E-box motif into pGL 3 -Basic ( Supplementary Fig. S7A ) and measured galectin-1 promoter activity in response to PTTG cotransfection by reporter assays. As shown in Supplementary Fig. S7B , PTTG transfection resulted in f2-fold induction of galectin-1 promoter activity compared with basal transcriptional level in EC9706 cells. PTTGinduced transactivation was attenuated f40% by PTTG RNAi cotransfection and was completely abolished by c-Myc RNAi.
Moreover, chromatin immunoprecipitation assays confirmed c-Myc binding to galectin-1 promoter in vivo. As shown in Fig. 5C , a specific 192-bp galectin-1 promoter PCR product was amplified from chromatin immunoprecipitation immunocomplex, which precipitated with anti-c-Myc antibody. Input DNA was used as positive control. Immunoprecipitation using irrelevant IgG as negative control did not show any amplification by PCR. Furthermore, PTTG up-regulation increased c-Myc association with galectin-1 promoter. PTTG-HA/EC9706 stable cells exhibited higher PTTG expression (f2.5-fold) than did control cells (Supplementary Fig. S8A ) and also showed increased c-Myc binding to galectin-1 promoter as assessed by chromatin immunoprecipitation (Supplementary Fig. S8B ).
In addition to suppressing galectin-1 transcriptional activity, c-Myc RNAi also decreased PTTG-induced galectin-1 protein expression (Supplementary Fig. S9 ). These data imply that the ability of PTTG to induce galectin-1 transcription and protein expression is mediated, at least partially, through c-Myc.
Discussion
PTTG is frequently up-regulated in human tumors and involved in metastasis. Increasing evidence reveals a correlation between PTTG overexpression and metastasis in breast, colon, lung, and prostate cancers (10) (11) (12) 17) . Nevertheless, the molecular mechanisms of PTTG action are still unclear. We have reported that ESCC cells and tumor tissues overexpress PTTG (14) . In this study, we present evidence that PTTG overexpression in esophageal cancer correlates with lymph node metastasis (Table 1) , which is consistent with a recent report by Shibata and colleagues (15) . Furthermore, we show that ectopic PTTG overexpression in EC9706 cells enhanced cell migration and invasion, and that impairing PTTG overexpression by siRNA significantly suppressed both effects ( Fig. 2A) . Of direct relevance, siRNA-mediated inhibition of endogenous PTTG protein in KYSE150 cells decreased their migratory and invasive activities (Fig. 2B) . In addition to promoting migration and invasion, PTTG is also able to stimulate angiogenesis by modulating VEGF secretion in human pituitary adenomas (16) . In a mouse model of follicular thyroid cancer, Pttg knockout Figure 3 . PTTG promotes lymph node metastasis in nude mice. PTTG expression was assessed by immunohistochemistry and H&E stained for histologic examination to judge metastasis. A, metastatic lymph nodes from PTTG-HA/EC9706 injected mice. a, H&E staining exhibits destroyed lymph node histologic structure by tumor cells; b, strong PTTG staining. B, normal lymph nodes from pcDNA 3 /EC9706 injected mice. c, H&E staining depicts normal histologic structure, with the entire lymphatic sinus and lymph follicle; d, negative PTTG staining. Magnification, Â40; Â200 (insets ). C, percentage of metastatic lymph nodes (LN+ )/total visually observable lymph nodes per mouse. P < 0.05 (t test). mice exhibited less angiogenesis and lung metastasis compared with wild type (27) . In other cellular systems, PTTG has been proved to up-regulate fibroblast growth factor-2 (28) and VEGF (19) expression and induce angiogenesis (5, 18, 19, 28, 29) . Thus, PTTG may endow cancer cells with increased migratory, invasive, and angiogenic abilities, thereby promoting increased metastatic potential.
Tumor cells provoke numerous alterations in their microenvironment as they progress toward metastasis (30) . Identifying changes in extracellular protein secretion during tumor cell metastasis is as important as investigating intracellular gene expression. Thus, we performed two-dimensional electrophoresis and MALDI-TOF MS to compare secretion profiling differences between conditioned media of PTTG-HA/EC9706 cells and that of control cells. As shown in Fig. 4 and Supplementary Tables S1 to S3, PTTG overexpression altered the secretory proteins of EC9706 cells and up-regulated the secretion and expression of several well-characterized metastasis-related molecules. Among them, S100A4, which enhances cell motility and promotes ECM remodeling and metastasis, has been characterized as a poor prognostic marker in a number of human tumors including ESCC (31) (32) (33) ; thioredoxin, which increases VEGF production and angiogenesis (34) , is associated with poor prognosis in colorectal cancer (35) ; and galectin-1, which facilitates various tumor metastases by promoting cell migration, invasion, angiogenesis, and evasion of immune response (21) (22) (23) (24) (25) , is regarded as a potential cancer target (21) . In contrast, secretion of TIMP-1 and TIMP-2, two members of the TIMP family that function to inhibit various MMP activities (36) (37) (38) , was downregulated by PTTG. In addition, PTTG also increased MMP-2 secretion but did not affect its mRNA and protein expression (Supplementary Fig. S10 ). Therefore, PTTG may enhance MMP-2 activity by down-regulating secretion of its inhibitor TIMP-2. Recently, S100A4 has been shown to bind Annexin II. The interaction accelerates plasminogen activation to generate plasmin, which is known to activate pro-MMPs (39). Thus, upregulated S100A4 expression may also contribute to MMP-2 activation on PTTG overexpression. Although the precise roles of these metastasis-related molecules modulated by PTTG require further investigation, we evidence that galectin-1 siRNA led to a significant decrease of PTTG-HA/EC9706 cell motility in vitro, which suggests that the effect of PTTG overexpression on cell migration and invasion is mediated, at least in part, via increased galectin-1 expression (Fig. 5B) . Above all, our findings indicate that PTTG endows cells with metastasis-promoting functions (enhanced migration, invasion, and angiogenesis) at least partially by modulating secretion and/or expression of multiple metastasis-associated molecules. Previous studies indicate that PTTG plays a role in transcriptional regulation (40) (41) (42) and functions in gene transactivation (26, 28, 41, 42) . PTTG induction in HeLaS3 cells results in increased cell proliferation through c-Myc activation (26) . PTTG-induced p53 expression is also mediated through c-Myc regulation in HEK293 cells (43) . We found that PTTG increased c-Myc transcriptional activity and expression, which is in accordance with recent reports (26) . PTTG binds to c-Myc promoter in a protein complex containing the upstream stimulatory factor (USF1) and up-regulates c-Myc transcriptional activity as a direct target (26) . In the present study, PTTG activated galectin-1 transcriptional activity and increased mRNA and protein expression ( Supplementary Figs. S4  and S7 ). Furthermore, we confirmed that c-Myc protein bound to galectin-1 promoter ( Fig. 5C; Supplementary Fig. S8 ), and c-Myc RNAi abolished both PTTG-induced galectin-1 transactivation and expression ( Supplementary Figs. S7 and S9 ). This finding suggests that PTTG-induced galectin-1 up-regulation is mediated, at least partially, through c-Myc activation.
Tail vein injection of stable PTTG-HA/EC9706 cells promoted lymph node metastases in nude mice. The data are consistent with the correlation between PTTG overexpression and lymph node metastasis in multiple tumors, including ESCC, and further strengthen the emerging view that PTTG exerts a metastatic function in ESCC. This finding implies that the metastatic property of ESCC may likely be dictated in the bulk of primary tumors cells (i.e., primary tumor cells that overexpress PTTG would possess enhanced potential to metastasize to the lymph nodes). The presence of lymph node metastasis usually represents an early prognostic indicator of tumor invasiveness and metastatic dissemination in many human tumors, including ESCC, and also indicates poor clinical outcome (3, 4) . Therefore, it would be of great value to use PTTG as a candidate early molecular prognostic marker for lymph node metastasis of primary ESCCs.
A study published during the revision of our manuscript investigated PTTG overexpression in ESCC tissues and cell lines and showed that inhibition of endogenous PTTG constrains cell motility (44) , hence supporting our present and previous studies (14) . Here, we used a similar PTTG RNAi strategy to attenuate cell motility, and we also generated PTTG stable cells (PTTG-HA/ EC9706) to show that ectopic PTTG overexpression results in increased cell invasion and migration. Notably, by performing twodimensional electrophoresis combined with mass spectrometric analysis, we were now able to identify altered proteomic profiles caused by PTTG up-regulation. This approach revealed the existence of multiple changes in protein secretion caused by PTTG, including several metastasis-related gene products such as galectin-1, S100A4, and TIMP-2. Most important, our current study elucidates novel molecular mechanisms of PTTG overexpression in promoting tumor metastasis, whereby PTTG modulates secretion and expression of metastasis-related factors, mediated by c-Myc, to facilitate cell motility.
In summary, we provide evidence that PTTG overexpression significantly correlates with lymph node metastasis in ESCC; in vitro and in vivo experiments indicate that PTTG increases cell migration and invasion to promote tumor metastasis by modulating secretion and expression of multiple metastasis-related factors such as galectin-1, S100A4, and TIMP-2. Moreover, we investigate the molecular mechanisms of PTTG in up-regulating galectin-1 expression through c-Myc activation. These results shed light on PTTG acting as a molecular biomarker to predict lymph node metastasis and expand current knowledge on the molecular mechanisms of PTTG in promoting ESCC metastasis.
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